Inspira Technologies Oxy
IINN

$1.22

3.17%

Market Cap: $22.6M

About: Inspira Technologies Oxy BHN Ltd is a specialty medical device company engaged in the research, development, manufacture, and marketing of proprietary respiratory support technology that is intended to provide an alternative to invasive mechanical ventilation (MV), which is the standard of care today for the treatment of respiratory failure. The respiratory care devices market is segmented geographically into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

Employees: 42

0

Funds holding %

of 6,728 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

52% more capital invested

Capital invested by funds: $174K [Q1] → $265K (+$90.8K) [Q2]

50% more funds holding

Funds holding: 6 [Q1] → 9 (+3) [Q2]

0.41% more ownership

Funds ownership: 0.64% [Q1] → 1.04% (+0.41%) [Q2]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for IINN.

See Analyst Rankings

Financial journalist opinion

Based on 6 articles about IINN published over the past 30 days

Zacks Investment Research

IINN Stock Gains on Second US Patent Approval for VORTX System

Inspira secures a second U.S. Patent approval for the VORTX orbiting blood oxygenation delivery system.

IINN Stock Gains on Second US Patent Approval for VORTX System

Inspira™ Secures a Second U.S. Patent Approval for Orbiting Blood Oxygenation Delivery System

To date, a combined total of 32 claims have been deemed novel for the core technology of the INSPIRA™ ART device Targeting treatment for 20 million ICU patients with respiratory failure annually, with many relying on mechanical ventilators, in a $19 billion industry RA'ANANA, Israel , Sept. 13, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N.

Inspira™ Secures a Second U.S. Patent Approval for Orbiting Blood Oxygenation Delivery System

Zacks Investment Research

Favorable Clinical Results for HYLA Sensor Might Boost Inspira Stock

IINN plans to report clinical results for its new HYLA blood sensor in open-heart surgery patients in the fourth quarter of 2024.

Favorable Clinical Results for HYLA Sensor Might Boost Inspira Stock

Inspira™ to Publish HYLA™ Clinical Results in Fourth Quarter 2024

The clip-on HYLA™ blood sensor, designed to alert physicians of immediate signs of changes in a patient's clinical condition without the need for intermittent actual blood samples, targets a potential $2.5 billion Point of Care testing and Arterial Blood Gas (ABG) analyzer market. RA'ANANA, Israel , Aug. 28, 2024 /PRNewswire/ -- Inspira Technologies OXY B.H.N.

Inspira™ to Publish HYLA™ Clinical Results in Fourth Quarter 2024

Zacks Investment Research

INSPIRA (IINN) CART Gets FDA Listing, to Enhance Healthcare

Inspira (IINN) announces FDA listing of its INSPIRA CART, designed for use with the ART100 system, enhancing healthcare delivery during cardiopulmonary bypass.

INSPIRA (IINN) CART Gets FDA Listing, to Enhance Healthcare

Inspira™ Technologies Announces FDA Listing and Market Readiness of New Product

RA'ANANA, Israel , Aug. 22, 2024 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) ("Inspira" or the "Company"), a leader in life-support technology innovation, today announces the U.S. Food and Drug Administration ("FDA") listing of its medical cart (INSPIRA™ CART) which has been custom designed for use with the INSPIRA™ ART100 system.

Inspira™ Technologies Announces FDA Listing and Market Readiness of New Product

Inspira™ Approached by Large Medical Company to Evaluate Operation of their Key Product with INSPIRA™ ART100 - Results Exceed 100% at Maximum Flow

RA'ANANA, Israel , Aug. 13, 2024 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) ("Inspira," "Inspira Technologies," or the "Company"), a trailblazer in life-support technology, today announced that it was approached by a leading medical technology company in the industry, to evaluate the operation of its proprietary key product in combination with the INSPIRA™ ART100 system.

Inspira™ Approached by Large Medical Company to Evaluate Operation of their Key Product with INSPIRA™ ART100 - Results Exceed 100% at Maximum Flow

Inspira™ Technologies Introduces the INSPIRA Cardi-ART, Aiming to Provide Oxygen to the Brain During Cardiac Arrest

Inspira's innovation targets life-saving intervention for patients with cardiac arrest, of which there are approximately 550,000 annual cardiac arrest events in the U.S., including 350,000 outside hospitals, where the survival rate is less than 10%. The INSPIRA Cardi-ART provides the Company a new market opportunity to target the $39.8 billion global cardiac arrest market.

Inspira™ Technologies Introduces the INSPIRA Cardi-ART, Aiming to Provide Oxygen to the Brain During Cardiac Arrest

Inspira™ Receives Israeli Regulatory Approval for the INSPIRA™ ART100 System

Approval follows the FDA clearance announced on May 28, 2024 RA'ANANA, Israel , July 11, 2024 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira"), a breakthrough medical technology company, is excited to announce the receipt of the Israeli Ministry of Health's medical devices and accessories ("AMAR") approval for the INSPIRA™ ART100, an Extra-Corporeal Membrane Oxygenation and Cardiopulmonary Bypass system.

Inspira™ Receives Israeli Regulatory Approval for the INSPIRA™ ART100 System

Zacks Investment Research

Inspira (IINN) Unveils Business Targets for 2024-25

Inspira (IINN) discloses business goals for 2024-25 with the rapid promotion of INSPIRA ART100 and the development of INSPIRA ART (Gen 2).

Inspira (IINN) Unveils Business Targets for 2024-25

See News Rankings